Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Csl Ltd ADR (OP:CSLLY)

71.02 -0.66 (-0.92%)
Streaming Delayed Price Updated: 3:58 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 93,277
Open 71.45
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 71.68
Today's Range 70.75 - 71.76
52wk Range 61.06 - 101.44
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
How KalVista Pharma Is Taking On A Rare But Deadly Disease
The company is working on the first new on-demand treatment for hereditary angioedema in 11 years. 
Via Investor's Business Daily

Performance

YTD
-18.5%
-18.5%
1 Month
+6.8%
+6.8%
3 Month
-15.3%
-15.3%
6 Month
-6.2%
-6.2%
1 Year
-29.5%
-29.5%

More News

Read More
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Life Sciences Investor Forum: Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
Via Benzinga
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
From ON24
Via Business Wire
Life Sciences Investor Forum Agenda Announced for June 11th-12th
From Virtual Investor Conferences
Via GlobeNewswire
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Via Benzinga
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Via Benzinga
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
CSL Joins Accumulus Synergy to Drive Industry Change
From Accumulus Synergy
Via GlobeNewswire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
From CSL Behring
Via GlobeNewswire
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
From Arcturus Therapeutics
Via Business Wire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Via Benzinga
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Via MarketBeat
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
Via Benzinga
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
From Arcturus Therapeutics Holdings Inc.
Via Business Wire

Frequently Asked Questions

Is Csl Ltd ADR publicly traded?
Yes, Csl Ltd ADR is publicly traded.
What exchange does Csl Ltd ADR trade on?
Csl Ltd ADR trades on the OTC Traded
What is the ticker symbol for Csl Ltd ADR?
The ticker symbol for Csl Ltd ADR is CSLLY on the OTC Traded
What is the current price of Csl Ltd ADR?
The current price of Csl Ltd ADR is 71.02
When was Csl Ltd ADR last traded?
The last trade of Csl Ltd ADR was at 10/17/25 03:58 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.